Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 151

1.

Use of prolonged bivalirudin infusions following percutaneous coronary intervention.

Moser LR, Nemerovski CW, Good KL.

Cardiovasc Drugs Ther. 2011 Jun;25(3):267-76. doi: 10.1007/s10557-011-6293-9. Review.

PMID:
21479645
[PubMed - indexed for MEDLINE]
2.

Safety and efficacy of a prolonged bivalirudin infusion after urgent and complex percutaneous coronary interventions: a descriptive study.

Cortese B, Micheli A, Picchi A, Bandinelli L, Brizi MG, Severi S, Limbruno U.

Coron Artery Dis. 2009 Aug;20(5):348-53. doi: 10.1097/MCA.0b013e32832cff08.

PMID:
19543084
[PubMed - indexed for MEDLINE]
3.

Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).

Patti G, Pasceri V, D'Antonio L, D'Ambrosio A, Macrì M, Dicuonzo G, Colonna G, Montinaro A, Di Sciascio G.

Am J Cardiol. 2012 Aug 15;110(4):478-84. doi: 10.1016/j.amjcard.2012.04.017. Epub 2012 May 12.

PMID:
22583760
[PubMed - indexed for MEDLINE]
4.

Two hour bivalirudin infusion after PCI for ST elevation myocardial infarction.

Anderson PR, Gogo PB, Ahmed B, Straight F, Terrien EF, Watkins MW, El Gharib N, Dauerman HL.

J Thromb Thrombolysis. 2011 May;31(4):401-6. doi: 10.1007/s11239-010-0528-7.

PMID:
21107655
[PubMed - indexed for MEDLINE]
5.

Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry.

Bangalore S, Cohen DJ, Kleiman NS, Regev-Beinart T, Rao SV, Pencina MJ, Mauri L; EVENT Registry Investigators, Boston, MA.

Circ Cardiovasc Interv. 2011 Oct 1;4(5):463-73. doi: 10.1161/CIRCINTERVENTIONS.111.961912. Epub 2011 Oct 4.

PMID:
21972401
[PubMed - indexed for MEDLINE]
Free Article
6.

Bivalirudin during primary PCI in acute myocardial infarction.

Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R; HORIZONS-AMI Trial Investigators.

N Engl J Med. 2008 May 22;358(21):2218-30. doi: 10.1056/NEJMoa0708191.

PMID:
18499566
[PubMed - indexed for MEDLINE]
Free Article
7.

Impact of diabetes mellitus on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: analysis from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial.

Witzenbichler B, Mehran R, Guagliumi G, Dudek D, Huber K, Kornowski R, Stuckey TD, Fahy M, Parise H, Stone GW.

JACC Cardiovasc Interv. 2011 Jul;4(7):760-8. doi: 10.1016/j.jcin.2011.04.008.

PMID:
21777884
[PubMed - indexed for MEDLINE]
Free Article
8.

Unfractionated heparin administration in patients treated with bivalirudin during primary percutaneous coronary intervention is associated lower mortality and target lesion thrombosis: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).

Koutouzis M, Lagerqvist B, James S, Omerovic E, Matejka G, Grip L, Albertsson P.

Heart. 2011 Sep;97(18):1484-8. doi: 10.1136/hrt.2011.224709. Epub 2011 Apr 12.

PMID:
21487123
[PubMed - indexed for MEDLINE]
9.

A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.

Gibson CM, Morrow DA, Murphy SA, Palabrica TM, Jennings LK, Stone PH, Lui HH, Bulle T, Lakkis N, Kovach R, Cohen DJ, Fish P, McCabe CH, Braunwald E; TIMI Study Group.

J Am Coll Cardiol. 2006 Jun 20;47(12):2364-73.

PMID:
16781360
[PubMed - indexed for MEDLINE]
Free Article
10.
11.

Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] trial).

Parodi G, Migliorini A, Valenti R, Bellandi B, Signorini U, Moschi G, Buonamici P, Cerisano G, Antoniucci D.

Am J Cardiol. 2010 Apr 15;105(8):1053-9. doi: 10.1016/j.amjcard.2009.12.001. Epub 2010 Feb 20.

PMID:
20381652
[PubMed - indexed for MEDLINE]
12.

Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.

Feldman DN, Wong SC, Gade CL, Gidseg DS, Bergman G, Minutello RM.

Am Heart J. 2007 Oct;154(4):695-701. Epub 2007 Aug 20.

PMID:
17892994
[PubMed - indexed for MEDLINE]
13.

Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.

Rajagopal V, Lincoff AM, Cohen DJ, Gurm HS, Hu T, Desmet WJ, Kleiman NS, Bittl JA, Feit F, Topol EJ.

Am Heart J. 2006 Jul;152(1):149-54.

PMID:
16824845
[PubMed - indexed for MEDLINE]
14.

Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial).

Lansky AJ, Mehran R, Cristea E, Parise H, Feit F, Ohman EM, White HD, Alexander KP, Bertrand ME, Desmet W, Hamon M, Stone GW.

Am J Cardiol. 2009 May 1;103(9):1196-203. doi: 10.1016/j.amjcard.2009.01.030.

PMID:
19406258
[PubMed - indexed for MEDLINE]
15.

Comparison of prolonged bivalirudin infusion versus intraprocedural in preventing myocardial damage after percutaneous coronary intervention in patients with angina pectoris.

Cortese B, Picchi A, Micheli A, Ebert AG, Parri F, Severi S, Limbruno U.

Am J Cardiol. 2009 Oct 15;104(8):1063-8. doi: 10.1016/j.amjcard.2009.06.005.

PMID:
19801025
[PubMed - indexed for MEDLINE]
16.

Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.

White HD, Ohman EM, Lincoff AM, Bertrand ME, Colombo A, McLaurin BT, Cox DA, Pocock SJ, Ware JA, Manoukian SV, Lansky AJ, Mehran R, Moses JW, Stone GW.

J Am Coll Cardiol. 2008 Sep 2;52(10):807-14. doi: 10.1016/j.jacc.2008.05.036.

PMID:
18755342
[PubMed - indexed for MEDLINE]
Free Article
17.

Comparison of bolus only with bolus plus infusion of bivalirudin in patients undergoing elective percutaneous coronary intervention: a retrospective observational study.

Sheikh-Taha M, Ghosn S.

J Pharm Pract. 2012 Oct;25(5):537-40. Epub 2012 May 9.

PMID:
22572222
[PubMed - indexed for MEDLINE]
18.

Bivalirudin administration during percutaneous coronary intervention: emphasis on high-risk patients.

Seybert AL.

Pharmacotherapy. 2002 Jun;22(6 Pt 2):112S-118S. Review.

PMID:
12064568
[PubMed - indexed for MEDLINE]
19.

Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry).

Amin AP, Kennedy KF, Pencina M, Berger P, Piana RN, Lopez J, Kleiman N, Cohen DJ; EVENT Investigators.

Am J Cardiol. 2011 Jun 15;107(12):1751-6. doi: 10.1016/j.amjcard.2011.02.331.

PMID:
21640216
[PubMed - indexed for MEDLINE]
20.

Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population.

Shelton R, Eftychiou C, Somers K, Liu A, Burton-Wood N, Anderson M, Makri L, Blaxill J, McLenachan J, Wheatcroft S, Greenwood J, Blackman D.

EuroIntervention. 2013 May 20;9(1):118-24. doi: 10.4244/EIJV9I1A17.

PMID:
23410540
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk